Bai, Charlotte J.
Madan, Nidhi
Alshahrani, Shaza
Aggarwal, Neelum T.
Volgman, Annabelle Santos
Article History
First Online: 27 August 2018
Compliance with Ethical Standards
:
: Charlotte Bai, Nidhi Madan, Shaza Alshahrani, and Annabelle Santos Volgman each declare no potential conflicts of interest.Neelum T. Aggarwal declares the following: Merck and Company-Adjudication Committee member (Consultant); Eli Lilly: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4 Study-Site Principal Investigator-Rush) ExternalRef removed Identifier: NCT02008357; Novartis/AMGEN: A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S1)-Site Principal Investigator-Rush: ExternalRef removed Identifier: NCT02565511; Novartis/AMGEN: A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S2)- Site Principal Investigator- Rush ExternalRef removed Identifier: NCT03131453; and Janssen: An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer’s Dementia (EARLY)-Site Principal Investigator-Rush ExternalRef removed Identifier: NCT02569398.
: This article does not contain any studies with human or animal subjects performed by any of the authors.